Home › Companies › SERES THERAPEUTICS INC. › 2024-2025
At SERES THERAPEUTICS INC.'s 2 shareholder meetings in the 2024-2025 proxy season (held September 26, 2024 and April 10, 2025), 73 asset managers reported how they voted on 13 ballot items in their SEC Form N-PX filings, covering 472 separate fund positions. On the most widely held item of the season, voted at the meeting held September 26, 2024 — TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, CERTAIN COMPENSATION THAT WILL OR MAY BECOME… — SERES THERAPEUTICS INC.'s filing reports the proposal as approved, with 75% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: SERES THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on September 26, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and SERES THERAPEUTICS INC.’s Form 8-K, filed April 14, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of April 10, 2025: 10 items on SERES THERAPEUTICS INC.’s Form 8-K, filed April 14, 2025: 1 approved · 9 without a stated outcome.
Meeting of September 26, 2024: 3 items on SERES THERAPEUTICS INC.’s Form 8-K, filed September 26, 2024: 3 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2023-2024 2024-2025
Explore SERES THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are SERES THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed April 14, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. SERES THERAPEUTICS INC. reported 2 meetings in this season; each is tabulated separately below, with its own filing.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Dennis A. Ausiello, M.D. | 57,960,418 | -- | -- | 32,806,373 | 24,624,114 | 64% | Not verified | — |
| Elect Director: Willard H. Dere, M.D. | 57,279,891 | -- | -- | 33,486,900 | 24,624,114 | 63% | Not verified | — |
| Elect Director: Eric D. Shaff | 55,393,022 | -- | -- | 35,373,769 | 24,624,114 | 61% | Not verified | — |
| 2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 | 99,949,589 | 5,599,971 | 9,841,345 | -- | 0 | 95% | Not verified | — |
| 3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers | 57,856,004 | 32,505,142 | 405,645 | -- | 24,624,114 | 64% | Not verified | — |
| 4. Approval of the Seres Therapeutics, Inc. 2025 Incentive Award Plan as an amendment and restatement of the Seres Therapeutics, Inc. 2015 Incentive Award Plan | 67,277,427 | 23,192,243 | 297,121 | -- | 24,624,114 | 74% | Not verified | — |
| 5. Approval of amendments to the Company's Restated Certificate of Incorporation, as amended ("Certificate of Incorporation") to effect a reverse stock split | 85,742,623 | 29,461,090 | 187,192 | -- | 0 | 74% | Not verified | — |
| 6. Approval of amendments to the Company's Certificate of Incorporation to clarify voting requirements to amend the number of shares of authorized Common Stock and preferred stock | 70,254,770 | 20,020,479 | 491,542 | -- | 24,624,114 | 78% | Not verified | — |
| 7. Approval of amendments to the Company's Certificate of Incorporation to eliminate supermajority voting requirements | 70,294,021 | 20,051,889 | 420,881 | -- | 24,624,114 | 78% | Not verified | — |
| 8. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Item 5, 6 or 7 | 85,038,069 | 29,311,765 | 1,041,071 | -- | 0 | 74% | Approved | — |
Source: SERES THERAPEUTICS INC., Form 8-K, filed with the SEC on April 14, 2025 — read the filing on EDGAR.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| 1. The Transaction Proposal | 77,099,464 | 7,081,341 | 156,974 | -- | -- | 92% | Approved | — |
| 2. The Compensation Proposal | 63,060,361 | 20,912,098 | 365,320 | -- | -- | 75% | Approved | — |
| 3. The Adjournment Proposal | 73,771,613 | 10,272,074 | 294,092 | -- | -- | 88% | Approved | — |
Source: SERES THERAPEUTICS INC., Form 8-K, filed with the SEC on September 26, 2024 — read the filing on EDGAR.
Each item below shows how the 73 asset managers that disclosed a SERES THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Meeting held April 10, 2025.
Combines 3 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Dennis A. Ausiello
SERES THERAPEUTICS INC.’s own tally for this item (“Elect Director: Dennis A. Ausiello, M.D.”): 57,960,418 for, 32,806,373 withheld, per its Form 8-K filed April 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 2,498,662 for, 3,732,310 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,492 | 0 | 0 | 3,489,689 | Withhold |
| Vanguard | 1,632,291 | 0 | 0 | 0 | For |
| Charles Schwab | 857,879 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 239,900 | Withhold |
| Victory Capital | 0 | 0 | 0 | 1,836 | Withhold |
| Advisors' Inner Circle Fund III | 0 | 0 | 0 | 471 | Withhold |
| Guggenheim | 0 | 0 | 0 | 414 | Withhold |
Meeting held April 10, 2025.
Combines 3 wordings of this item as funds reported it.
61% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Eric D. Shaff
SERES THERAPEUTICS INC.’s own tally for this item (“Elect Director: Eric D. Shaff”): 55,393,022 for, 35,373,769 withheld, per its Form 8-K filed April 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 61% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 2,741,283 for, 3,489,689 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,492 | 0 | 0 | 3,489,689 | Withhold |
| Vanguard | 1,632,291 | 0 | 0 | 0 | For |
| Charles Schwab | 857,879 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 239,900 | 0 | 0 | 0 | For |
| Victory Capital | 1,836 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 471 | 0 | 0 | 0 | For |
| Guggenheim | 414 | 0 | 0 | 0 | For |
Meeting held April 10, 2025.
Combines 3 wordings of this item as funds reported it.
63% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Willard H. Dere
SERES THERAPEUTICS INC.’s own tally for this item (“Elect Director: Willard H. Dere, M.D.”): 57,279,891 for, 33,486,900 withheld, per its Form 8-K filed April 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 63% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 2,741,283 for, 3,489,689 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,492 | 0 | 0 | 3,489,689 | Withhold |
| Vanguard | 1,632,291 | 0 | 0 | 0 | For |
| Charles Schwab | 857,879 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 239,900 | 0 | 0 | 0 | For |
| Victory Capital | 1,836 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 471 | 0 | 0 | 0 | For |
| Guggenheim | 414 | 0 | 0 | 0 | For |
Meeting held September 26, 2024.
Combines 2 wordings of this item as funds reported it.
92% Approved · of votes cast
Description as filed by funds: To approve the proposed sale (the "Transaction") of Seres' VOWST microbiome therapeutic business to Societe des Produits Nestle S.A. ("SPN") pursuant to the terms of the Asset Purchase Agreement, dated as of August 5, 2024, by and between Seres and SPN (the "Transaction Proposal").
SERES THERAPEUTICS INC.’s own tally for this item (“1. The Transaction Proposal”): 77,099,464 for, 7,081,341 against — passed, per its Form 8-K filed September 26, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The number of votes cast for and against, as well as abstention votes, with respect to each proposal presented at the Special Meeting was as follows: Proposal No. 1: The Transaction Proposal The Company's stockholders approved the proposed sale of the Company's VOWST Business to SPN pursuant to the…”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 12,828,756 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,731,634 | 0 | 0 | 0 | For |
| Vanguard | 3,577,877 | 0 | 0 | 0 | For |
| Charles Schwab | 268,204 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 250,000 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 446 | 0 | 0 | 0 | For |
| Guggenheim | 414 | 0 | 0 | 0 | For |
| Victory Capital | 181 | 0 | 0 | 0 | For |
Meeting held April 10, 2025.
78% Majority: yes · of votes cast
Description as filed by funds: APPROVAL OF AMENDMENTS TO OUR RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO ELIMINATE SUPERMAJORITY VOTING REQUIREMENTS.
SERES THERAPEUTICS INC.’s own tally for this item (“7. Approval of amendments to the Company's Certificate of Incorporation to eliminate supermajority voting requirements”): 70,294,021 for, 20,051,889 against, per its Form 8-K filed April 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 6,230,972 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,498,181 | 0 | 0 | 0 | For |
| Vanguard | 1,632,291 | 0 | 0 | 0 | For |
| Charles Schwab | 857,879 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 239,900 | 0 | 0 | 0 | For |
| Victory Capital | 1,836 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 471 | 0 | 0 | 0 | For |
| Guggenheim | 414 | 0 | 0 | 0 | For |
Meeting held April 10, 2025.
78% Majority: yes · of votes cast
Description as filed by funds: APPROVAL OF AMENDMENTS TO OUR RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO CLARIFY VOTING REQUIREMENTS TO AMEND THE NUMBER OF SHARES OF AUTHORIZED COMMON STOCK AND PREFERRED STOCK.
SERES THERAPEUTICS INC.’s own tally for this item (“6. Approval of amendments to the Company's Certificate of Incorporation to clarify voting requirements to amend the number of shares of authorized Common Stock and preferred stock”): 70,254,770 for, 20,020,479 against, per its Form 8-K filed April 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 78% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 6,230,972 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,498,181 | 0 | 0 | 0 | For |
| Vanguard | 1,632,291 | 0 | 0 | 0 | For |
| Charles Schwab | 857,879 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 239,900 | 0 | 0 | 0 | For |
| Victory Capital | 1,836 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 471 | 0 | 0 | 0 | For |
| Guggenheim | 414 | 0 | 0 | 0 | For |
Meeting held April 10, 2025.
74% Majority: yes · of votes cast
Description as filed by funds: APPROVAL OF AMENDMENTS TO OUR RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED, TO EFFECT A REVERSE STOCK SPLIT.
SERES THERAPEUTICS INC.’s own tally for this item (“5. Approval of amendments to the Company's Restated Certificate of Incorporation, as amended ("Certificate of Incorporation") to effect a reverse stock split”): 85,742,623 for, 29,461,090 against, per its Form 8-K filed April 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 6,230,972 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,498,181 | 0 | 0 | 0 | For |
| Vanguard | 1,632,291 | 0 | 0 | 0 | For |
| Charles Schwab | 857,879 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 239,900 | 0 | 0 | 0 | For |
| Victory Capital | 1,836 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 471 | 0 | 0 | 0 | For |
| Guggenheim | 414 | 0 | 0 | 0 | For |
Meeting held April 10, 2025.
74% Approved · of votes cast
Description as filed by funds: APPROVAL OF AN ADJOURNMENT OF THE ANNUAL MEETING, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE NOT SUFFICIENT VOTES AT THE TIME OF THE ANNUAL MEETING TO APPROVE PROPOSALS 5, 6 OR 7.
SERES THERAPEUTICS INC.’s own tally for this item (“8. Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Item 5, 6 or 7”): 85,038,069 for, 29,311,765 against — passed, per its Form 8-K filed April 14, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Item 8 - Approval of an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there were not sufficient votes at the time of the Annual Meeting to approve Item 5, 6 or 7.”
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 6,230,972 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,498,181 | 0 | 0 | 0 | For |
| Vanguard | 1,632,291 | 0 | 0 | 0 | For |
| Charles Schwab | 857,879 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 239,900 | 0 | 0 | 0 | For |
| Victory Capital | 1,836 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 471 | 0 | 0 | 0 | For |
| Guggenheim | 414 | 0 | 0 | 0 | For |
Meeting held September 26, 2024.
88% Approved · of votes cast
Description as filed by funds: TO APPROVE THE ADJOURNMENT OF THE SPECIAL MEETING TO A LATER DATE OR DATES, IF NECESSARY, TO SOLICIT ADDITIONAL PROXIES IF THERE ARE INSUFFICIENT VOTES TO ADOPT THE TRANSACTION PROPOSAL AT THE TIME OF THE SPECIAL MEETING.
SERES THERAPEUTICS INC.’s own tally for this item (“3. The Adjournment Proposal”): 73,771,613 for, 10,272,074 against — passed, per its Form 8-K filed September 26, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 3: The Adjournment Proposal The Company's stockholders approved the proposal to adjourn the Special Meeting to a later date or dates, if necessary, to solicit additional proxies to approve the Transaction Proposal as follows:”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 11,869,048 for, 959,708 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,771,926 | 959,708 | 0 | 0 | Mixed |
| Vanguard | 3,577,877 | 0 | 0 | 0 | For |
| Charles Schwab | 268,204 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 250,000 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 446 | 0 | 0 | 0 | For |
| Guggenheim | 414 | 0 | 0 | 0 | For |
| Victory Capital | 181 | 0 | 0 | 0 | For |
Meeting held April 10, 2025.
74% Majority: yes · of votes cast
Description as filed by funds: APPROVAL OF THE SERES THERAPEUTICS, INC. 2025 INCENTIVE AWARD PLAN AS AN AMENDMENT AND RESTATEMENT OF THE SERES THERAPEUTICS, INC. 2015 INCENTIVE AWARD PLAN, WHICH IS SCHEDULED TO EXPIRE IN 2025.
SERES THERAPEUTICS INC.’s own tally for this item (“4. Approval of the Seres Therapeutics, Inc. 2025 Incentive Award Plan as an amendment and restatement of the Seres Therapeutics, Inc. 2015 Incentive Award Plan”): 67,277,427 for, 23,192,243 against, per its Form 8-K filed April 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 6,230,501 for, 471 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,498,181 | 0 | 0 | 0 | For |
| Vanguard | 1,632,291 | 0 | 0 | 0 | For |
| Charles Schwab | 857,879 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 239,900 | 0 | 0 | 0 | For |
| Victory Capital | 1,836 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 471 | 0 | 0 | Against |
| Guggenheim | 414 | 0 | 0 | 0 | For |
Meeting held September 26, 2024.
Combines 5 wordings of this item as funds reported it.
75% Approved · of votes cast
Description as filed by funds: TO APPROVE, ON A NON-BINDING, ADVISORY BASIS, CERTAIN COMPENSATION THAT WILL OR MAY BECOME PAYABLE TO OUR NAMED EXECUTIVE OFFICERS IN CONNECTION WITH THE TRANSACTION.
SERES THERAPEUTICS INC.’s own tally for this item (“2. The Compensation Proposal”): 63,060,361 for, 20,912,098 against — passed, per its Form 8-K filed September 26, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal No. 2: The Compensation Proposal The Company's stockholders approved, on a non-binding, advisory basis, certain compensation that will or may become payable to the Company's named executive officers in connection with the Transaction as follows:”
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,731,634 | 0 | 0 | 0 | For |
| Vanguard | 3,577,877 | 0 | 0 | 0 | For |
| Charles Schwab | 268,204 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 250,000 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 446 | 0 | 0 | 0 | For |
| Guggenheim | 414 | 0 | 0 | 0 | For |
| Victory Capital | 181 | 0 | 0 | 0 | For |
Fund voting reports, all 7 managers: 12,828,756 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 17,159,059 | 0 | 0 | 0 | For |
| BlackRock | 1,466,992 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,090,610 | 0 | 0 | 0 | For |
| Charles Schwab | 268,204 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 250,000 | 0 | 0 | 0 | For |
| Soviero Asset Management, LP | 180,000 | 0 | 0 | 0 | For |
| Northern Trust | 168,136 | 0 | 0 | 0 | For |
| Point72 | 114,878 | 0 | 0 | 0 | For |
| Janney Montgomery Scott LLC | 75,098 | 0 | 0 | 0 | For |
| T. Rowe Price | 67,392 | 0 | 0 | 0 | For |
| State Street | 65,248 | 0 | 0 | 0 | For |
| Vanguard | 60,722 | 0 | 0 | 0 | For |
| Pennant Investors, LP | 58,460 | 0 | 0 | 0 | For |
| HighTower Advisors, LLC | 55,000 | 0 | 0 | 0 | For |
| Prudential/PGIM | 27,870 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 22,480 | 0 | 0 | 0 | For |
| Focus Partners Wealth | 20,968 | 0 | 0 | 0 | For |
| Wilkinson Global Asset Management LLC | 13,265 | 0 | 0 | 0 | For |
| Invesco | 10,938 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 9,557 | 0 | 0 | 0 | For |
| Beacon Pointe Advisors, LLC | 8,162 | 0 | 0 | 0 | For |
| Ethic Inc. | 7,047 | 0 | 0 | 0 | For |
| BROWN ADVISORY INC | 5,000 | 0 | 0 | 0 | For |
| Russell Investments | 3,698 | 0 | 0 | 0 | For |
| FIDELIS CAPITAL PARTNERS, LLC | 3,083 | 0 | 0 | 0 | For |
Institutional-manager reports, all 59 managers: 21,233,714 for, 308 against. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held April 10, 2025.
Combines 6 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: APPROVAL, ON AN ADVISORY (NON-BINDING) BASIS, OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.
SERES THERAPEUTICS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers”): 57,856,004 for, 32,505,142 against, per its Form 8-K filed April 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 64% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 8,492 | 3,489,689 | 0 | 0 | Against |
| Vanguard | 1,632,291 | 0 | 0 | 0 | For |
| Charles Schwab | 857,879 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 239,900 | 0 | 0 | 0 | For |
| Victory Capital | 1,836 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 471 | 0 | 0 | 0 | For |
| Guggenheim | 414 | 0 | 0 | 0 | For |
Fund voting reports, all 7 managers: 2,741,283 for, 3,489,689 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Flagship Pioneering Inc. | 23,117,045 | 0 | 0 | 0 | For |
| Fidelity | 0 | 13,177,710 | 0 | 0 | Against |
| Charles Schwab | 857,879 | 0 | 0 | 0 | For |
| BlackRock | 257,192 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 239,900 | 0 | 0 | 0 | For |
| Northern Trust | 186,054 | 0 | 0 | 0 | For |
| State Street | 183,748 | 0 | 0 | 0 | For |
| Vanguard | 91,834 | 0 | 0 | 0 | For |
| HighTower Advisors, LLC | 70,000 | 0 | 0 | 0 | For |
| Two Sigma | 32,206 | 0 | 0 | 0 | For |
| Janney Montgomery Scott LLC | 29,000 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 20,480 | 0 | 0 | 0 | For |
| Wilkinson Global Asset Management LLC | 13,265 | 0 | 0 | 0 | For |
| CAPTRUST FINANCIAL ADVISORS | 13,100 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 11,890 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 9,557 | 0 | 0 | 0 | For |
| Beacon Pointe Advisors, LLC | 7,912 | 0 | 0 | 0 | For |
| FIDELIS CAPITAL PARTNERS, LLC | 2,901 | 0 | 0 | 0 | For |
| Ethic Inc. | 2,737 | 0 | 0 | 0 | For |
| CIBC Asset Management Inc | 2,620 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 2,000 | 0 | 0 | 0 | For |
| Victory Capital | 1,836 | 0 | 0 | 0 | For |
| Freedom Investment Management, Inc. | 1,734 | 0 | 0 | 0 | For |
| COLDSTREAM CAPITAL MANAGEMENT INC | 1,597 | 0 | 0 | 0 | For |
| MML INVESTORS SERVICES, LLC | 1,269 | 0 | 0 | 0 | For |
Institutional-manager reports, all 55 managers: 25,167,964 for, 13,178,018 against. Showing the 25 largest; every one is in the interactive database (link above).
Meeting held April 10, 2025.
Combines 2 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
SERES THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025”): 99,949,589 for, 5,599,971 against, per its Form 8-K filed April 14, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 7 asset managers below reported 6,230,501 for, 471 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 3,498,181 | 0 | 0 | 0 | For |
| Vanguard | 1,632,291 | 0 | 0 | 0 | For |
| Charles Schwab | 857,879 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 239,900 | 0 | 0 | 0 | For |
| Victory Capital | 1,836 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 471 | 0 | 0 | Against |
| Guggenheim | 414 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 174,358,753 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 5.01% |
| 2 | Vanguard | 2.05% |
| 3 | Charles Schwab | 0.15% |
| 4 | BRIDGEWAY FUNDS INC | 0.14% |
| 5 | Advisors' Inner Circle Fund III | <0.01% |
| 6 | Guggenheim | <0.01% |
| 7 | Victory Capital | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 9.84% |
| 2 | BlackRock | 0.84% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 0.63% |
| 4 | Charles Schwab | 0.15% |
| 5 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.14% |
| 6 | Soviero Asset Management, LP | 0.10% |
| 7 | Northern Trust | 0.10% |
| 8 | Point72 | 0.07% |
| 9 | Janney Montgomery Scott LLC | 0.04% |
| 10 | T. Rowe Price | 0.04% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with Flagship Pioneering | 13.26% | DEF14A |
| Nestlé S.A. | 12.49% | DEF14A |
| Eric D. Shaff | 1.66% | DEF14A |
| Thomas J. DesRosier | 0.70% | DEF14A |
| Lisa von Moltke, M.D. | 0.41% | DEF14A |
| Dennis A. Ausiello, M.D. | 0.21% | DEF14A |
| Richard N. Kender | 0.18% | DEF14A |
| Kurt C. Graves | 0.18% | DEF14A |
| Stephen A. Berenson | 0.17% | DEF14A |
| Willard H. Dere, M.D. | 0.16% | DEF14A |
Percentages above are of 174,358,753 shares outstanding, as reported by SERES THERAPEUTICS INC. on its Form 10-K dated March 7, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from SERES THERAPEUTICS INC.’s 10-K dated March 7, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
SERES THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page).
proxyvotesnow.com, “SERES THERAPEUTICS (MCRB) 2024-2025 Annual & Special Meetings”, https://proxyvotesnow.com/company/seres-therapeutics-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.